Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients - Sorbonne Université
Journal Articles OncoImmunology Year : 2021

Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients

Guido Kroemer
Oliver Kepp

Abstract

High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.

Domains

Cancer
Fichier principal
Vignette du fichier
2162402X.2021.pdf (812.75 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-03467607 , version 1 (06-12-2021)

Identifiers

Cite

Guido Kroemer, Oliver Kepp. Radiochemotherapy-induced elevations of plasma HMGB1 levels predict therapeutic responses in cancer patients. OncoImmunology, 2021, 10 (1), ⟨10.1080/2162402x.2021.2005859⟩. ⟨hal-03467607⟩
99 View
25 Download

Altmetric

Share

More